GlassScriptPhysician profile
John R Mathias
NPI 1639239643
$570.93
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $130 · 2021: $201.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $180.58 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $172.08 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.65 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.18 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.60 | 2020-2021 | |
| Novo Nordisk INC | $15.64 | 2020 | |
| Alfasigma USA, INC. | $14.82 | 2020 | |
| Qol Medical, LLC | $13.80 | 2019 | |
| Intercept Pharmaceuticals, INC. | $11.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mathias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.